Aeolus Pharmaceuticals (AOLS) Stock Overview
A biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
AOLS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Aeolus Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.0001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 9,900.00% |
| 3 Year Change | 0% |
| 5 Year Change | -99.17% |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| AOLS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -0.6% | 0.6% |
| 1Y | 9,900.0% | 24.2% | 18.4% |
Return vs Industry: AOLS exceeded the US Pharmaceuticals industry which returned 25% over the past year.
Return vs Market: AOLS exceeded the US Market which returned 15.5% over the past year.
Price Volatility
| AOLS volatility | |
|---|---|
| AOLS Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AOLS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine AOLS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | n/a | n/a | www.aeoluspharma.com |
Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents.
Aeolus Pharmaceuticals, Inc. Fundamentals Summary
| AOLS fundamental statistics | |
|---|---|
| Market cap | US$15.21k |
| Earnings (TTM) | -US$4.09m |
| Revenue (TTM) | US$771.00k |
Is AOLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AOLS income statement (TTM) | |
|---|---|
| Revenue | US$771.00k |
| Cost of Revenue | US$2.49m |
| Gross Profit | -US$1.72m |
| Other Expenses | US$2.37m |
| Earnings | -US$4.09m |
Last Reported Earnings
Jun 30, 2017
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did AOLS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/27 05:43 |
| End of Day Share Price | 2026/01/23 00:00 |
| Earnings | 2017/06/30 |
| Annual Earnings | 2016/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aeolus Pharmaceuticals, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kevin DeGeeter | Ladenburg Thalmann & Company |
| Nathan Cali | NOBLE Capital Markets, Inc. |
| Joseph Pantginis | Roth Capital Partners |